FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4284889145> ?p ?o ?g. }

• W4284889145 endingPage "508" @default.
• W4284889145 startingPage "489" @default.
• W4284889145 abstract "Blood-based (BB) biomarkers for Aβ and tau can indicate pathological processes in the brain, in the early pathological, even pre-symptomatic stages in Alzheimer's disease. However, the relation between BB biomarkers and AD-related processes in the brain in the earliest pre-pathology stage before amyloid pathology develops, and their relation with total brain concentrations of Aβ and tau, is poorly understood. This stage presents a critical window for the earliest prevention of AD. Preclinical models with well-defined temporal progression to robust amyloid and tau pathology provide a unique opportunity to study this relation and were used here to study the link between BB biomarkers with AD-related processes in pre- and pathological stages. We performed a cross-sectional study at different ages assessing the link between BB concentrations and AD-related processes in the brain. This was complemented with a longitudinal analysis and with analysis of age-related changes in a small cohort of human subjects. We found that BB-tau concentrations increased in serum, correlating with progressive development of tau pathology and with increasing tau aggregates and p-tau concentrations in brain in TauP301S mice (PS19) developing tauopathy. BB-Aβ42 concentrations in serum decreased between 4.5 and 9 months of age, correlating with the progressive development of robust amyloid pathology in APP/PS1 (5xFAD) mice, in line with previous findings. Most importantly, BB-Aβ42 concentrations significantly increased between 1.5 and 4.5 months, i.e., in the earliest pre-pathological stage, before robust amyloid pathology develops in the brain, indicating biphasic BB-Aβ42 dynamics. Furthermore, increasing BB-Aβ42 in the pre-pathological phase, strongly correlated with increasing Aβ42 concentrations in brain. Our subsequent longitudinal analysis of BB-Aβ42 in 5xFAD mice, confirmed biphasic BB-Aβ42, with an initial increase, before decreasing with progressive robust pathology. Furthermore, in human samples, BB-Aβ42 concentrations were significantly higher in old (> 60 years) compared to young (< 50 years) subjects, as well as to age-matched AD patients, further supporting age-dependent increase of Aβ42 concentrations in the earliest pre-pathological phase, before amyloid pathology. Also BB-Aβ40 concentrations were found to increase in the earliest pre-pathological phase both in preclinical models and human subjects, while subsequent significantly decreasing concentrations in the pathological phase were characteristic for BB-Aβ42. Together our data indicate that BB biomarkers reflect pathological processes in brain of preclinical models with amyloid and tau pathology, both in the pathological and pre-pathological phase. Our data indicate a biphasic pattern of BB-Aβ42 in preclinical models and a human cohort. And most importantly, we here show that BB-Aβ increased and correlated with increasing concentrations of Aβ in the brain, in the earliest pre-pathological stage in a preclinical model. Our data thereby identify a novel critical window for prevention, using BB-Aβ as marker for accumulating Aβ in the brain, in the earliest pre-pathological stage, opening new avenues for personalized early preventive strategies against AD, even before amyloid pathology develops." @default.
• W4284889145 created "2022-07-09" @default.
• W4284889145 creator A5017397935 @default.
• W4284889145 creator A5018015963 @default.
• W4284889145 creator A5032581949 @default.
• W4284889145 creator A5034195360 @default.
• W4284889145 creator A5051810215 @default.
• W4284889145 creator A5055261000 @default.
• W4284889145 creator A5073131907 @default.
• W4284889145 creator A5077454656 @default.
• W4284889145 creator A5084759166 @default.
• W4284889145 date "2022-07-07" @default.
• W4284889145 modified "2023-10-13" @default.
• W4284889145 title "Blood-based Aβ42 increases in the earliest pre-pathological stage before decreasing with progressive amyloid pathology in preclinical models and human subjects: opening new avenues for prevention" @default.
• W4284889145 cites W1929267935 @default.
• W4284889145 cites W1967823816 @default.
• W4284889145 cites W1987096559 @default.
• W4284889145 cites W2052742260 @default.
• W4284889145 cites W2054007740 @default.
• W4284889145 cites W2057249855 @default.
• W4284889145 cites W2075193321 @default.
• W4284889145 cites W2092198587 @default.
• W4284889145 cites W2096963202 @default.
• W4284889145 cites W2103982815 @default.
• W4284889145 cites W2108493635 @default.
• W4284889145 cites W2109355761 @default.
• W4284889145 cites W2111642028 @default.
• W4284889145 cites W2115017507 @default.
• W4284889145 cites W2134711807 @default.
• W4284889145 cites W2148681333 @default.
• W4284889145 cites W2152709750 @default.
• W4284889145 cites W2154813265 @default.
• W4284889145 cites W2159462479 @default.
• W4284889145 cites W2170644095 @default.
• W4284889145 cites W2171250577 @default.
• W4284889145 cites W2327547544 @default.
• W4284889145 cites W2525940741 @default.
• W4284889145 cites W2535103378 @default.
• W4284889145 cites W2582524520 @default.
• W4284889145 cites W2724272654 @default.
• W4284889145 cites W2785757836 @default.
• W4284889145 cites W2787666045 @default.
• W4284889145 cites W2798054687 @default.
• W4284889145 cites W2895381107 @default.
• W4284889145 cites W2900969253 @default.
• W4284889145 cites W2902155257 @default.
• W4284889145 cites W2912579052 @default.
• W4284889145 cites W2920387298 @default.
• W4284889145 cites W2944020290 @default.
• W4284889145 cites W2948815538 @default.
• W4284889145 cites W2952677120 @default.
• W4284889145 cites W2971816621 @default.
• W4284889145 cites W2989446795 @default.
• W4284889145 cites W3000745939 @default.
• W4284889145 cites W3009441391 @default.
• W4284889145 cites W3012272172 @default.
• W4284889145 cites W3025418474 @default.
• W4284889145 cites W3044633524 @default.
• W4284889145 cites W3088634533 @default.
• W4284889145 cites W3108125496 @default.
• W4284889145 cites W3119309452 @default.
• W4284889145 cites W3123214671 @default.
• W4284889145 cites W3131174931 @default.
• W4284889145 cites W3159530258 @default.
• W4284889145 cites W3164390524 @default.
• W4284889145 cites W3165581912 @default.
• W4284889145 cites W3168610515 @default.
• W4284889145 cites W3174265554 @default.
• W4284889145 cites W3178454960 @default.
• W4284889145 cites W3206313727 @default.
• W4284889145 cites W4200548419 @default.
• W4284889145 cites W4206179494 @default.
• W4284889145 cites W4210987525 @default.
• W4284889145 cites W4211213171 @default.
• W4284889145 cites W4213114226 @default.
• W4284889145 cites W4213423501 @default.
• W4284889145 cites W4280534580 @default.
• W4284889145 doi "https://doi.org/10.1007/s00401-022-02458-9" @default.
• W4284889145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35796870" @default.
• W4284889145 hasPublicationYear "2022" @default.
• W4284889145 type Work @default.
• W4284889145 citedByCount "4" @default.
• W4284889145 countsByYear W42848891452022 @default.
• W4284889145 countsByYear W42848891452023 @default.
• W4284889145 crossrefType "journal-article" @default.
• W4284889145 hasAuthorship W4284889145A5017397935 @default.
• W4284889145 hasAuthorship W4284889145A5018015963 @default.
• W4284889145 hasAuthorship W4284889145A5032581949 @default.
• W4284889145 hasAuthorship W4284889145A5034195360 @default.
• W4284889145 hasAuthorship W4284889145A5051810215 @default.
• W4284889145 hasAuthorship W4284889145A5055261000 @default.
• W4284889145 hasAuthorship W4284889145A5073131907 @default.
• W4284889145 hasAuthorship W4284889145A5077454656 @default.
• W4284889145 hasAuthorship W4284889145A5084759166 @default.
• W4284889145 hasBestOaLocation W42848891451 @default.
• W4284889145 hasConcept C142724271 @default.
• W4284889145 hasConcept C146357865 @default.
• W4284889145 hasConcept C151730666 @default.

• next